When Novartis launched Kymriah, the first FDA-approved CAR T-cell therapy in 2017, which innovative pricing model did they pioneer to address the therapy's high cost?

CAR T-cell therapy represents one of the most significant breakthroughs in cancer treatment in recent decades. These personalized treatments modify a patient's own immune cells to attack cancer. However, their introduction to the market created unprecedented pricing challenges in the medical industry. This poll tests your knowledge of how these revolutionary therapies were initially priced and the strategies that shaped their market entry.

This is a live public trivia poll on AIPolls.Net. Vote and see real-time results.

Outcomes-based pricing: Novartis would only receive full payment if patients responded to the treatment within a specified timeframe
Subscription model: Hospitals paid an annual fee for unlimited access to the therapy for their patients
Tiered pricing: The cost was determined by the specific cancer type and stage being treated
Installment plan: The $475,000 treatment could be paid by insurers in monthly installments over five years